Narayana Hrudayalaya to buy Panacea Biotec’s NewRise Healthcare for Rs180 crore
- Sanskrit most suitable for machine learning, AI: Ram Nath Kovind
- Aadhaar seeding must for bank accounts under KYC norms, says new RBI guidelines
- IMF, World Bank must develop strategy for enhancing public debt transparency: India
- CPM rules out alliance with Congress, but to have ‘understanding’
- SCO meet: No bilaterals between foreign, defence ministers of India, Pakistan
New Delhi: Bengaluru-based hospital chain Narayana Hrudayalaya Ltd has acquired Gurgaon-based multi-speciality hospital NewRise Healthcare Pvt. Ltd from drug maker Panacea Biotech Ltd for Rs180 crore.
The 230-bed hospital is in the final stages of completion and is likely to be commissioned within the next nine months, Narayana Hrudayalaya said in a stock exchange filing on Friday, adding that the acquisition is expected to strengthen its position in the north.
Narayana Hrudayalaya currently has a network of 23 hospitals and seven heart centres across India.
As per the agreement, Panacea Biotech and its associate firm PanEra Biotech Pvt. Ltd will sell 100% equity shares and 100% preference shares, respectively, in NewRise Healthcare to Narayana Hrudayalaya.
In a separate stock exchange filing, Panacea Biotech said that NewRise Healthcare’s net worth was Rs55.31 crore as of 31 March 2017.
Panacea Biotech had entered into a corporate debt restructuring exercise in 2014-15 and the company had total liabilities of Rs1,807.43 crore as of 31 March 2016.
On Friday, shares of Narayana Hrudayalaya ended down 0.2% at Rs317.65 apiece on BSE, while Panacea Biotech’s shares closed 3.6% higher at Rs164.85 each. The benchmark Sensex index fell 0.2% to 29,365.30 points.